Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prime Medicine, Inc.

1.69
+0.330024.26%
Post-market: 1.68-0.0100-0.59%19:55 EDT
Volume:4.96M
Turnover:8.02M
Market Cap:216.02M
PE:-1.05
High:1.71
Open:1.42
Low:1.40
Close:1.36
Loading ...

BRIEF-Prime Medicine Unveils Program For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)

Reuters
·
18 Mar

Prime Medicine Price Target Maintained With a $10.00/Share by Citizens Capital Markets

Dow Jones
·
04 Mar

Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Prime Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Mar

TD Cowen Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)

TIPRANKS
·
28 Feb

Prime Medicine reports FY24 EPS ($1.65) vs ($2.18) last year

TIPRANKS
·
28 Feb

Prime Medicine FY 2024 GAAP EPS $(1.65) Beats $(1.66) Estimate, Sales $2.983M Beats $929.100K Estimate

Benzinga
·
28 Feb

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire
·
28 Feb

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
24 Feb

Prime Drink Group Announces The Appointment Of A New Chief Financial Officer

T-Reuters
·
14 Jan

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
01 Jan

Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?

Insider Monkey
·
31 Dec 2024

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey
·
29 Dec 2024

Prime Medicine Files for Resale of 11 Million Shares

MT Newswires Live
·
13 Dec 2024

Prime Medicine Inc Files for Resale of up to 11 Mln Common Shares by the Selling Stockholder - SEC Filing

THOMSON REUTERS
·
13 Dec 2024

JMP Securities Initiates Prime Medicine at Market Outperform With $10 Price Target

MT Newswires Live
·
10 Dec 2024